Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
ISIS EIF4E Rx · 2 trials · 2 indications
| Arm | Type | Description |
|---|---|---|
| Part 1 Cohort 1 | EXPERIMENTAL | - |
| Part 1 Cohort 2 | EXPERIMENTAL | - |
| Part 2 Arm A | EXPERIMENTAL | - |
| Part 2 Arm B | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| ISIS EIF4E Rx | DRUG | 800 mg ISIS EIF4E Rx administered as a 3-hour intravenous infusion on Days 1, 8 and 15 of each 21 day cycle. |
| Prednisone | DRUG | 5 mg administered orally twice daily on days 1, 8, 15 and 22 of each cycle |
| Docetaxel | DRUG | 75 mg/m2 administered as a 1-hour intravenous infusion on day 1 of each cycle |
| Paclitaxel | DRUG | 200 mg/m2 administered as a 3-hour intravenous infusion on Day 1 of each 21 day cycle |
| Carboplatin | DRUG | AUC 6.0 mg/mL/min administered as a 1-hour intravenous infusion on Day 1 of each 21 day cycle |
Inclusion Criteria: * Provide written informed consent prior to Screening. * Age ≥ 18 years. * Histological or cytological diagnosis of adenocarcinoma of the prostate. * Metastatic disease for which no curative therapy exists and for which systemic chemotherapy is indicated. * Progression of diseas...
ISIS EIF4E Rx is an investigational oncology drug being studied for the treatment of Non-small Cell Lung Cancer and Castrate-Resistant Prostate Cancer. It is currently in Phase 1 clinical development and is not approved by the FDA.
ISIS EIF4E Rx is being developed by Ionis Pharmaceuticals, Inc. (NASDAQ: IONS). The company is conducting clinical trials to evaluate the drug's safety and tolerability in combination with other cancer therapies.
ISIS EIF4E Rx is in Phase 1 clinical development. Two Phase 1 trials have been completed, one in Castrate-Resistant Prostate Cancer and one in Non-small Cell Lung Cancer. The drug remains investigational and has not received FDA approval.
ISIS EIF4E Rx has been studied in two completed Phase 1 trials. NCT01234025 evaluated the drug in combination with docetaxel and prednisone in Castrate-Resistant Prostate Cancer. NCT01234038 evaluated it with carboplatin and paclitaxel in Non-small Cell Lung Cancer.
Yes, ISIS EIF4E Rx is classified as a small molecule therapeutic. It is being developed as an oncology treatment and has been tested in combination with standard chemotherapy regimens in clinical trials.